Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Understanding Disease Management in Systemic Mastocytosis - A Look at Pipeline Products from Blueprint & Deciphera

Ticker(s): BPMC, DCPH

Who's the expert?

Name: Dr John Mascarenhas - MD

Institution: Mount Sinai  

  • Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai.
  • Currently manages 40-50 patients with Systemic mastocytosis including ISM and ASM.
  • PI of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium (MPD-RC) and has served as PI/Study Chair of multiple early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and AML.

Interview Questions
Q1.

Please describe your clinical practice; roughly how many patients with Systemic mastocytosis do you currently manage?

Added By: c_admin
Q2.

Do you currently prescribe Midostaurin (Rydapt)?

Added By: c_admin
Q3.

What is your current first-line therapy for this disease?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.